PE20142182A1 - Inhibidores de iap - Google Patents

Inhibidores de iap

Info

Publication number
PE20142182A1
PE20142182A1 PE2014001069A PE2014001069A PE20142182A1 PE 20142182 A1 PE20142182 A1 PE 20142182A1 PE 2014001069 A PE2014001069 A PE 2014001069A PE 2014001069 A PE2014001069 A PE 2014001069A PE 20142182 A1 PE20142182 A1 PE 20142182A1
Authority
PE
Peru
Prior art keywords
iap inhibitors
refers
compound
iap
inhibitors
Prior art date
Application number
PE2014001069A
Other languages
English (en)
Inventor
Frederick Cohen
Lewis J Gazzard
Vickie Hsiao-Wei Tsui
John A Flygare
Original Assignee
Curis Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc, Genentech Inc filed Critical Curis Inc
Publication of PE20142182A1 publication Critical patent/PE20142182A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

SE REFIERE AL COMPUESTO (2-OXAZOL-2-IL-4-FENIL-TIAZOL-5-IL)-AMIDA DEL ACIDO (S)-1-[(S)-2-CICLOHEXIL-2-((S)-2-METILAMINO-PROPIONILAMINO)-ACETIL]-PIRROLIDIN-2-CARBOXILICO. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN INHIBIDOR DE IAP (INHIBIDORES DE APOPTOSIS) QUE ES UTIL EN EL TRATAMIENTO DEL CANCER.
PE2014001069A 2012-01-03 2013-01-03 Inhibidores de iap PE20142182A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261582760P 2012-01-03 2012-01-03

Publications (1)

Publication Number Publication Date
PE20142182A1 true PE20142182A1 (es) 2015-01-16

Family

ID=48695302

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001069A PE20142182A1 (es) 2012-01-03 2013-01-03 Inhibidores de iap

Country Status (41)

Country Link
US (6) US8716236B2 (es)
EP (2) EP3133073B1 (es)
JP (2) JP5747137B2 (es)
KR (3) KR101855566B1 (es)
CN (2) CN104159897A (es)
AR (2) AR089623A1 (es)
AU (1) AU2013202780B2 (es)
BR (1) BR112014016637B1 (es)
CA (1) CA2861637C (es)
CL (1) CL2014001770A1 (es)
CO (1) CO7020915A2 (es)
CR (1) CR20140367A (es)
CY (2) CY1118371T1 (es)
DK (2) DK2800749T3 (es)
EC (1) ECSP14011792A (es)
ES (2) ES2672809T3 (es)
HK (1) HK1203949A1 (es)
HR (2) HRP20161381T1 (es)
HU (2) HUE031305T2 (es)
IL (2) IL233386A (es)
LT (2) LT2800749T (es)
MA (1) MA35895B1 (es)
ME (2) ME03084B (es)
MX (1) MX336294B (es)
MY (1) MY178390A (es)
NO (1) NO2755614T3 (es)
NZ (1) NZ627480A (es)
PE (1) PE20142182A1 (es)
PH (2) PH12014501534A1 (es)
PL (2) PL3133073T3 (es)
PT (2) PT3133073T (es)
RS (2) RS55327B1 (es)
RU (2) RU2728789C2 (es)
SG (1) SG11201403784QA (es)
SI (2) SI2800749T1 (es)
SM (1) SMT201600357B (es)
TR (1) TR201808088T4 (es)
TW (1) TWI503318B (es)
UA (1) UA114417C2 (es)
WO (1) WO2013103703A1 (es)
ZA (1) ZA201405535B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2755614T3 (es) * 2012-01-03 2018-03-31
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用
PL3712162T3 (pl) * 2017-11-13 2022-11-14 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. MIMETYKI SMAC STOSOWANE JAKO INHIBITORY lAP I ICH ZASTOSOWANIE
US11639354B2 (en) 2018-07-31 2023-05-02 Fimecs, Inc. Heterocyclic compound
JPWO2021020585A1 (es) 2019-07-31 2021-02-04
MX2022008874A (es) 2020-01-20 2022-08-11 Astrazeneca Ab Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
WO2023239422A2 (en) 2021-10-22 2023-12-14 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0975608B1 (en) 1997-04-15 2005-06-15 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
KR100984459B1 (ko) * 2004-07-02 2010-09-29 제넨테크, 인크. Iap의 억제제
ATE477254T1 (de) * 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
EP2102229B1 (en) 2006-10-12 2014-03-26 Novartis AG Pyrrolydine derivatives as iap inhibitors
MX2009011783A (es) 2007-04-30 2009-12-04 Genentech Inc Inhibidores de iap.
NO2755614T3 (es) 2012-01-03 2018-03-31
USD690416S1 (en) 2012-12-12 2013-09-24 Pharmajet, Inc. Needle-free syringe

Also Published As

Publication number Publication date
IL233386A (en) 2016-08-31
DK3133073T3 (en) 2018-06-18
CY1118371T1 (el) 2017-06-28
CY1120355T1 (el) 2019-07-10
CO7020915A2 (es) 2014-08-11
PT3133073T (pt) 2018-06-18
JP5747137B2 (ja) 2015-07-08
US9586991B2 (en) 2017-03-07
CA2861637A1 (en) 2013-07-11
CA2861637C (en) 2017-07-18
US8716236B2 (en) 2014-05-06
HUE037760T2 (hu) 2018-09-28
BR112014016637B1 (pt) 2022-06-14
US11963994B2 (en) 2024-04-23
EP3133073B1 (en) 2018-05-02
TWI503318B (zh) 2015-10-11
SG11201403784QA (en) 2014-08-28
ES2594856T3 (es) 2016-12-23
US20170136084A1 (en) 2017-05-18
US11096982B2 (en) 2021-08-24
CN107915728A (zh) 2018-04-17
ME02526B (me) 2017-02-20
MX2014007895A (es) 2015-03-19
IL242314A (en) 2016-08-31
US20130172264A1 (en) 2013-07-04
KR20150065960A (ko) 2015-06-15
RS55327B1 (sr) 2017-03-31
CR20140367A (es) 2015-02-18
KR101855566B1 (ko) 2018-05-04
MY178390A (en) 2020-10-12
LT2800749T (lt) 2016-10-25
US20220211797A1 (en) 2022-07-07
ECSP14011792A (es) 2015-12-31
PT2800749T (pt) 2016-10-24
RS57438B1 (sr) 2018-09-28
PH12014501534B1 (en) 2014-10-08
SMT201600357B (it) 2016-11-10
HUE031305T2 (hu) 2017-07-28
TR201808088T4 (tr) 2018-06-21
JP2015199738A (ja) 2015-11-12
KR101917992B1 (ko) 2018-11-13
UA114417C2 (uk) 2017-06-12
PL3133073T3 (pl) 2018-09-28
IL233386A0 (en) 2014-08-31
ME03084B (me) 2019-01-20
US20190224269A1 (en) 2019-07-25
PH12014501534A1 (en) 2014-10-08
EP2800749A4 (en) 2015-08-05
HRP20180976T1 (hr) 2018-08-10
CN107915728B (zh) 2021-04-30
AU2013202780A1 (en) 2013-07-18
WO2013103703A1 (en) 2013-07-11
RU2728789C2 (ru) 2020-07-31
SI2800749T1 (sl) 2016-11-30
RU2016124658A (ru) 2018-12-04
PH12015501038B1 (en) 2015-09-21
US20160102119A1 (en) 2016-04-14
AR089623A1 (es) 2014-09-03
TW201333001A (zh) 2013-08-16
RU2014130171A (ru) 2016-02-27
HK1203949A1 (en) 2015-11-06
LT3133073T (lt) 2018-06-25
EP3133073A2 (en) 2017-02-22
HRP20161381T1 (hr) 2016-12-02
EP2800749A1 (en) 2014-11-12
AU2013202780B2 (en) 2015-04-16
BR112014016637A8 (pt) 2017-07-04
KR20140107670A (ko) 2014-09-04
NZ627480A (en) 2016-04-29
ZA201405535B (en) 2017-08-30
CL2014001770A1 (es) 2015-04-17
AR123542A2 (es) 2022-12-14
DK2800749T3 (en) 2016-11-07
KR101553792B1 (ko) 2015-09-16
ES2672809T3 (es) 2018-06-18
JP2015504072A (ja) 2015-02-05
NO2755614T3 (es) 2018-03-31
CN104159897A (zh) 2014-11-19
EP2800749B1 (en) 2016-09-21
KR20180051646A (ko) 2018-05-16
EP3133073A3 (en) 2017-03-22
PH12015501038A1 (en) 2015-09-21
US20140235551A1 (en) 2014-08-21
BR112014016637A2 (pt) 2017-06-13
PL2800749T3 (pl) 2017-01-31
RU2593259C2 (ru) 2016-08-10
MA35895B1 (fr) 2014-12-01
MX336294B (es) 2016-01-14
SI3133073T1 (en) 2018-06-29
US9238675B2 (en) 2016-01-19
RU2016124658A3 (es) 2019-09-09

Similar Documents

Publication Publication Date Title
PE20142182A1 (es) Inhibidores de iap
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
CR20140405A (es) Apoptosis señal reguladores del inhibidor de quinasa
CR20150416A (es) Inhibidores de cdc7
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
PE20150887A1 (es) Compuestos de benceno sustituidos
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
CR20150447A (es) Nuevos derivados de pirazol
GT201400090A (es) 2-tiopirimidinonas
CR20150204A (es) Nuevos derivados de piridina
BR112015019624A2 (pt) quinazolinas como inibidores de quinase
CR20160448A (es) Nuevos derivados de piridina
BR112016028022A2 (pt) compostos de sulfonamida e seus usos como inibidores de stat5
EA201591259A1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
BR112014012521A2 (pt) novos derivados de pirrolidina como inibidores de catepsina
CU20150173A7 (es) COMPOSICIÓN FARMACÉUTICA QUE INCLUYE UN INHIBIDOR DE LA HMG-Coa REDUCTASA QUE MINIMIZA LA INTERACCIÓN DEL ÁCIDO ÁCIDO ACETILSALICÍLICO CON LA ESTATINA
CR20160227A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
EA201690561A1 (ru) Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i
BR112014019220A8 (pt) Novos derivados de pirrolidina
ES2570976T3 (es) Derivado de 2,4-diaminopirimidina bicíclico condensado como inhibidor dual de ALK y FAK
ECSP16024798A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024805A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa

Legal Events

Date Code Title Description
FG Grant, registration